Nat Med:自身免疫性风湿病患者能接种CoronaVac灭活疫苗吗?

2021-07-30 MedSci原创 MedSci原创

这些数据支持ARD患者接种CoronaVac疫苗,表明它的短期免疫原性有所降低但可接受。该试验仍在进行中,以评估CoronaVac疫苗在ARD患者中的长期有效性/免疫原性。

CoronaVac是一种灭活的SARS-CoV-2疫苗,已被多个国家批准用于紧急情况。然而,它在免疫缺陷个体中的免疫原性尚未完全明确。

近日,顶级医学期刊Nature Medicine上发表了一篇研究文章,研究人员在910名自身免疫性风湿病(ARD)成人和182名年龄和性别频率匹配的健康成人(对照组,CG)中进行了一项前瞻性4期对照试验(no.NCT04754698, CoronavRheum),他们接种了两剂CoronaVac疫苗。

该研究的主要结局为与CG组相比,ARD组第二次注射后6周(第69天(D69))抗SARS-CoV-2 IgG血清转化(SC)和中和抗体(NAb)阳性均降低≥15%。次要结局是在D28时IgG SC和NAb阳性,在D28时IgG滴度和中和活性以及D69时的疫苗安全性。

与CG组相比,ARD组D69时抗SARS-CoV-2 IgG SC (70.4 vs. 95.5%,P<0.001)和NAb阳性(56.3 vs. 79.3%,P<0.001)均达到了预先设定的终点。此外,ARD患者在D69时IgG滴度(12.1 vs. 29.7, P<0.001)和中和活性(58.7 vs. 64.5%,P=0.013)也较低。与CG相比,ARD患者在D28时IgG(18.7 vs. 34.6%,P<0.001)和NAb(20.6 vs. 36.3%,P<0.001)的阳性率较低。该研究未发现中度/重度不良事件发生。

由此可见,这些数据支持ARD患者接种CoronaVac疫苗,表明它的短期免疫原性有所降低但可接受。该试验仍在进行中,以评估CoronaVac疫苗在ARD患者中的长期有效性/免疫原性。

原始出处:

Medeiros-Ribeiro, et al.Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nature Medicine.2021. https://www.nature.com/articles/s41591-021-01469-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2078864, encodeId=abb920e8864ce, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Fri Aug 06 18:47:52 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885338, encodeId=99ae188533874, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 14 19:47:52 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611186, encodeId=34ee16111862a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 01 14:47:52 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004123, encodeId=8636100412352, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210731/fc14291e6c8443659a1e4e65e70b3410/ce99307505254ab6b9713f9b1cc83db0.jpg, createdBy=3f3c5539617, createdName=LeoLiao, createdTime=Sat Jul 31 00:14:00 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2078864, encodeId=abb920e8864ce, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Fri Aug 06 18:47:52 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885338, encodeId=99ae188533874, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 14 19:47:52 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611186, encodeId=34ee16111862a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 01 14:47:52 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004123, encodeId=8636100412352, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210731/fc14291e6c8443659a1e4e65e70b3410/ce99307505254ab6b9713f9b1cc83db0.jpg, createdBy=3f3c5539617, createdName=LeoLiao, createdTime=Sat Jul 31 00:14:00 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
    2021-11-14 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=2078864, encodeId=abb920e8864ce, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Fri Aug 06 18:47:52 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885338, encodeId=99ae188533874, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 14 19:47:52 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611186, encodeId=34ee16111862a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 01 14:47:52 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004123, encodeId=8636100412352, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210731/fc14291e6c8443659a1e4e65e70b3410/ce99307505254ab6b9713f9b1cc83db0.jpg, createdBy=3f3c5539617, createdName=LeoLiao, createdTime=Sat Jul 31 00:14:00 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2078864, encodeId=abb920e8864ce, content=<a href='/topic/show?id=f48865242bb' target=_blank style='color:#2F92EE;'>#活疫苗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65242, encryptionId=f48865242bb, topicName=活疫苗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e4aa106, createdName=crystal0562, createdTime=Fri Aug 06 18:47:52 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1885338, encodeId=99ae188533874, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun Nov 14 19:47:52 CST 2021, time=2021-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611186, encodeId=34ee16111862a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sun Aug 01 14:47:52 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1004123, encodeId=8636100412352, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210731/fc14291e6c8443659a1e4e65e70b3410/ce99307505254ab6b9713f9b1cc83db0.jpg, createdBy=3f3c5539617, createdName=LeoLiao, createdTime=Sat Jul 31 00:14:00 CST 2021, time=2021-07-31, status=1, ipAttribution=)]
    2021-07-31 LeoLiao

    学习了

    0

相关资讯

科兴生物发布重磅研究结果!接种第三剂科兴新冠灭活疫苗后中和抗体水平显著增高

7月26日,据科兴控股生物技术有限公司官方微信公众号“疫苗之益”消息,2021年7月25日,由江苏省疾病预防控制中心疫苗评价所联合复旦大学公共卫生学院、科兴控股生物技术有限公司

NEJM:真实世界研究数据表明科兴SARS-CoV-2灭活疫苗可有效预防Covid-19

新冠病毒的大流行给全球带来了极大的疾病负担,据WHO统计,截至7月14日,

安徽新冠疫苗应急采购结果出炉,三款国产灭活疫苗均纳入使用

安徽省医药集中采购服务中心近日公布的文件显示三款国产灭活疫苗均纳入使用。

Lancet Infect Dis:氢氧化铝吸附脊髓灰质炎疫苗有效预防1-3型脊髓灰质炎

接种1/10剂量的 IPV-Al疫苗2剂或3剂即可达到较好的免疫预防效果

Lancet Infect Dis:BBIBP-CorV新冠肺炎灭活疫苗1/2期研究获得成功

BBIBP-CorV新冠肺炎灭活疫苗是安全的,耐受性良好。在接种后第42天在所有疫苗受者均产生了SARS-Cov-2体液反应。基础接种联合1次强化接种的免疫应答效果优于单次双倍剂量接种

高福谈新冠疫苗研发:灭活疫苗中国走得很快 反馈的效果也很好

近日,多款新冠疫苗陆续获批并开始在多国大规模接种。中国攻坚克难,以严谨规范态度进行疫苗研发……目前全球疫苗有哪些不同类型?中国的疫苗研发经历了怎样的过程?科学家对新冠肺炎病